Ionsys

Country: Unjoni Ewropea

Lingwa: Ingliż

Sors: EMA (European Medicines Agency)

Ixtrih issa

Ingredjent attiv:

fentanyl hydrochloride

Disponibbli minn:

Janssen-Cilag International NV

Kodiċi ATC:

N02AB03

INN (Isem Internazzjonali):

fentanyl

Grupp terapewtiku:

Analgesics

Żona terapewtika:

Pain, Postoperative

Indikazzjonijiet terapewtiċi:

Management of acute moderate to severe post-operative pain for use in a hospital setting only

Sommarju tal-prodott:

Revision: 3

L-istatus ta 'awtorizzazzjoni:

Withdrawn

Data ta 'l-awtorizzazzjoni:

2006-01-24

Fuljett ta 'informazzjoni

                                Medicinal product no longer authorised
B.
PACKAGE LEAFLET
22
Medicinal product no longer authorised
PACKAGE LEAFLET: INFORMATION FOR THE USER
IONSYS 40 MICROGRAMS PER DOSE IONTOPHORETIC TRANSDERMAL SYSTEM
fentanyl
Read all of this leaflet carefully before you start using this
medicine.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, please ask your doctor or your
nurse.
-
This product has been prescribed for you. Do not pass it on to others.
It may harm them, even if
their symptoms are the same as yours.
-
If any of the side-effects gets serious, or if you notice any side
effects not listed in this leaflet,
please tell your doctor or nurse.
IN THIS LEAFLET:
1.
What IONSYS is and what it is used for
2.
Before you use IONSYS
3.
How to use IONSYS
4.
Possible side effects
5.
How to store IONSYS
6.
Further Information
1.
WHAT IONSYS IS AND WHAT IT IS USED FOR
IONSYS is a system that you can operate to control your pain.
IONSYS IS USED IN HOSPITAL ONLY
, to treat pain after an operation. You control your own treatment,
under the guidance of medical staff.
2.
BEFORE YOU USE IONSYS
DO NOT USE IONSYS:
-
IF YOU ARE ALLERGIC
_(hypersensitive) _
to fentanyl, adhesive bandages or tapes, or any of the
ingredients listed below.
TAKE SPECIAL CARE WITH IONSYS
Tell your doctor or nurse
-
If you already have problems with your lungs or trouble breathing
-
If you have problems with your heart, liver or kidneys
-
If you get headaches or have had a head injury
-
If you have any difficulty hearing
-
If you have abnormally slow bowel movements
TAKING OTHER MEDICINES
Some medicines can affect the way IONSYS works, or make it more likely
that you’ll have side
effects.
CHECK WITH YOUR DOCTOR
if you’re taking:
-
any medicine which makes you sleepy or drowsy (such as other
morphine-related painkillers,
antihistamines or tranquillisers)
-
muscle relaxants (these may be prescribed for back pain)
-
ritonavir or other CYP3A4 inhibitors (medicines that help control HIV
infection)
-
antidepressants call
                                
                                Aqra d-dokument sħiħ
                                
                            

Karatteristiċi tal-prodott

                                Medicinal product no longer authorised
_ _
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
1
Medicinal product no longer authorised
1.
NAME OF THE MEDICINAL PRODUCT
IONSYS 40 micrograms per dose iontophoretic transdermal system.
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each IONSYS system contains 10.8 mg fentanyl hydrochloride equivalent
to 9.7 mg of fentanyl and
delivers 40 micrograms fentanyl per dose, to a maximum of 3.2 mg (80
doses).
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Iontophoretic transdermal system (ITS).
IONSYS is composed of a compact electronic controller and two hydrogel
reservoirs, one of which
contains fentanyl hydrochloride in a gel formulation for needle free,
on-demand delivery. The upper
part of the product is white and contains the identifier ‘IONSYS
™
’.
4.
CLINICAL PARTICULARS
4.1.
THERAPEUTIC INDICATIONS
IONSYS is indicated for the management of acute moderate to severe
post-operative pain for use in a
hospital setting only.
4.2.
POSOLOGY AND METHOD OF ADMINISTRATION
IONSYS should be restricted to hospital use only. Due to the well
known potential of abuse of
fentanyl physicians should evaluate patients for a history of drug
abuse (see section 4.4).
Special precautions for disposal should be followed (see section 6.6).
IONSYS should only be activated by the patient.
Before any surgery, the healthcare professional should ensure that the
patient has been properly
informed on how to use IONSYS post-operatively.
IONSYS delivers 40 micrograms per on-demand dose up to a maximum of
240 micrograms (6 doses
each of 10 minutes duration) per hour but not more than a maximum of
80 doses within a 24 hour
period. Patients should be titrated to an acceptable level of
analgesia prior to initiating use of IONSYS.
_ _
The system should only be activated by the patient in response to
pain. IONSYS will operate for 24
hours following completion of the first dose or for 80 doses,
whichever comes first, and then becomes
inoperative. If the patient attempts to initiate a dose 
                                
                                Aqra d-dokument sħiħ
                                
                            

Dokumenti f'lingwi oħra

Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Bulgaru 17-05-2018
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Bulgaru 17-05-2018
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Spanjol 17-05-2018
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Spanjol 17-05-2018
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Ċek 17-05-2018
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Ċek 17-05-2018
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Daniż 17-05-2018
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Daniż 17-05-2018
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Ġermaniż 17-05-2018
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Ġermaniż 17-05-2018
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Ġermaniż 28-01-2011
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Estonjan 17-05-2018
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Estonjan 17-05-2018
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Estonjan 28-01-2011
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Grieg 17-05-2018
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Grieg 17-05-2018
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Franċiż 21-07-2013
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Franċiż 21-07-2013
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Franċiż 28-01-2011
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Taljan 17-05-2018
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Taljan 17-05-2018
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Latvjan 17-05-2018
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Latvjan 17-05-2018
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Litwanjan 17-05-2018
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Litwanjan 17-05-2018
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Litwanjan 28-01-2011
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Ungeriż 17-05-2018
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Ungeriż 17-05-2018
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Ungeriż 28-01-2011
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Malti 17-05-2018
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Malti 17-05-2018
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Olandiż 17-05-2018
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Olandiż 17-05-2018
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Olandiż 28-01-2011
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Pollakk 17-05-2018
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Pollakk 17-05-2018
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Portugiż 17-05-2018
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Portugiż 17-05-2018
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Portugiż 28-01-2011
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Rumen 17-05-2018
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Rumen 17-05-2018
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Slovakk 17-05-2018
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Slovakk 17-05-2018
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Sloven 17-05-2018
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Sloven 17-05-2018
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Finlandiż 17-05-2018
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Finlandiż 17-05-2018
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Finlandiż 28-01-2011
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Svediż 17-05-2018
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Svediż 17-05-2018

Fittex twissijiet relatati ma 'dan il-prodott

Ara l-istorja tad-dokumenti